

# **Gene Therapy**

## **Part I: Technologies & Markets**

by

**Prof. K. K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
Basel, Switzerland

**June 2018**

**A Jain PharmaBiotech Report**

## **AUTHOR'S BIOGRAPHY**

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and US, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is a consultant at Jain PharmaBiotech. Prof. Jain's 476 publications include 30 books (6 as editor + 24 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.

Prof. Jain has edited "Drug Delivery Systems" (2008, 2<sup>nd</sup> ed 2014) and "Drug Delivery to the Central Nervous System" (2010), both published by Humana/Springer. His other recent books include "Handbook of Nanomedicine" (Springer 2008; Chinese edition, Peking University Press 2011; 3<sup>rd</sup> ed Springer 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2<sup>nd</sup> ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition. Chemical Industry Press 2016, 2<sup>nd</sup> ed Springer 2017) and "Handbook of Neuroprotection" (Springer 2011). Books that contain chapters on gene therapy include: Applications of Biotechnology in Cardiovascular Therapeutics (Springer 2011), Applications of Biotechnology in Neurology (Springer 2013), and Applications of Biotechnology in Oncology (Springer 2014). He has also edited "Applied Neurogenomics" (Springer in 2015).

## **ABOUT THIS REPORT**

Prof. Jain wrote the first commercial report on Gene Therapy in 1995, which was published by PJB Publication, London. This was followed by reports on Gene Therapy Vectors and Cancer Gene Therapy (1996). A report on Gene Therapy of Neurological Disorders was published by Decision Resources in 1997. In 1998, Prof. Jain wrote a Textbook of Gene Therapy, which was the first book on this subject to be translated into the Chinese language in 2000. A book on gene therapy companies was published in 2000 by John Wiley & Sons and continued to be updated online at Wiley's web site until 2003. In 2004, when the copyright reverted to Prof. Jain, it became part II of the Gene Therapy report. This report supercedes and updates all the previous books as well as reports.

**June 2018**  
**Copyright © 2018 by**

**Jain PharmaBiotech**  
**Bläsiring 7**  
**CH-4057 Basel**  
**Switzerland**

**Tel & Fax:** +4161-6924461  
**Email:** [info@pharmabiotech.ch](mailto:info@pharmabiotech.ch)  
**Web site:** <http://pharmabiotech.ch/>

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>21</b>
<b>1. Introduction .....</b>	<b>23</b>
<b>Definitions .....</b>	<b>23</b>
<b>Historical evolution of gene therapy .....</b>	<b>23</b>
<b>Relation of gene therapy to other biotechnologies.....</b>	<b>25</b>
<b>Molecular biological basics for gene therapy .....</b>	<b>26</b>
Genome.....	26
DNA .....	26
RNA .....	27
<i>Alternative RNA splicing.....</i>	<i>28</i>
Genes.....	28
<i>Silent gene mutations.....</i>	<i>29</i>
Gene regulation .....	29
Gene expression .....	30
ENCODE .....	31
Chromosomes .....	31
Telomeres.....	32
Mitochondria .....	32
Proteins.....	33
<b>2. Gene Therapy Technologies .....</b>	<b>35</b>
<b>Classification of gene therapy techniques.....</b>	<b>35</b>
<b>Ex vivo and in vivo gene therapy .....</b>	<b>36</b>
Ex vivo gene therapy.....	36
In vivo gene therapy .....	37
<b>Physical methods of gene transfer.....</b>	<b>37</b>
Electroporation .....	37
Applications of electroporation .....	38
<i>Clinical applications of electroporation .....</i>	<i>39</i>
<i>Advantages of electroporation .....</i>	<i>40</i>
<i>Limitations of electroporation .....</i>	<i>40</i>
Hydrodynamic .....	40
Microinjection.....	41
Particle bombardment .....	41
Ultrasound-mediated transfection .....	43
Molecular vibration.....	44
Application of pulsed magnetic field and superparamagnetic nanoparticles .....	44
Gene transfection using laser irradiation .....	44
Photochemical transfection.....	45
<b>Chemical methods of gene transfer .....</b>	<b>45</b>
<b>Gene repair and replacement.....</b>	<b>45</b>
Gene repair by single-stranded oligonucleotides.....	46
History and current status of chimeraplasty .....	46
<b>Genome editing.....</b>	<b>46</b>
Gene editing by zinc finger nucleases. ....	46
Gene editing by using short synthetic oligonucleotides.....	47
Genome engineering by using TALENs .....	47
Gene editing by homing endonucleases .....	47
Genome editing by using CRISPR system .....	48
<i>A method for generating genome-wide gRNA libraries for CRISPR.....</i>	<i>49</i>
<i>CRISPR vs other gene editing tools .....</i>	<i>49</i>
<i>CRISPR for studying human embryogenesis .....</i>	<i>50</i>
<i>CRISPR system for creating animal models of human diseases.....</i>	<i>50</i>
<i>CRISPR/Cas9 technology for drug discovery .....</i>	<i>51</i>
<i>Expanding the range of Cas9s .....</i>	<i>51</i>
<i>Inducible CRISPR/Cas9 for multiple gene targeting .....</i>	<i>51</i>
<i>Photoactivatable CRISPR-Cas9.....</i>	<i>52</i>
<i>Protein delivery and genome editing.....</i>	<i>52</i>
Potential clinical applications of CRISPR systems.....	52
<i>Autosomal dominant retinitis pigmentosa.....</i>	<i>53</i>
<i>Correction of a gene mutation in the human embryo .....</i>	<i>53</i>
<i>Glaucoma .....</i>	<i>54</i>
<i>PERV blockage by CRISPR to facilitate xenotransplantation .....</i>	<i>54</i>
<i>RNA editing with CRISPR.....</i>	<i>55</i>
<i>Use of CRISPR for <math>\beta</math>-hemoglobinopathies .....</i>	<i>56</i>
<i>Use of CRISPR to restore hereditary hearing loss .....</i>	<i>56</i>

<i>Clinical trial of CRISPR in human cancer</i> .....	57
<i>Complications and limitations of CRISPR/Cas9 technology</i> .....	58
<i>Companies developing CRISPR technology</i> .....	58
Clinical studies of gene editing.....	59
Targeted genome editing by artificial nucleases.....	60
Future gene editing tools.....	60
Comparison of gene editing with techniques for suppression of gene mutations.....	60
<b>Base editing of the genome</b> .....	<b>62</b>
Base editing by protein engineering.....	62
Adenine base editors for genomic DNA.....	62
<b>mRNA gene therapy</b> .....	<b>63</b>
Spliceosome mediated RNA trans-splicing.....	63
<b>Vectors for gene therapy</b> .....	<b>63</b>
Basic considerations.....	63
Use of genes as pharmaceuticals.....	64
The ideal vector for gene therapy.....	64
Viral vectors.....	65
<i>Adenovirus vectors</i> .....	65
<i>Adeno-associated virus vectors</i> .....	67
<i>Alphavirus vectors</i> .....	70
<i>Baculovirus vectors</i> .....	71
<i>Foamy virus vectors</i> .....	71
<i>Herpes simplex virus vectors</i> .....	71
<i>Lentiviral vectors</i> .....	74
<i>Multicistronic retroviral vectors</i> .....	75
<i>Retroviral vectors</i> .....	75
<i>Oncogenic potential of retroviral vectors</i> .....	77
<i>Quantification of viral vectors</i> .....	77
<i>Future of viral vectors</i> .....	77
<i>Companies using viral vectors</i> .....	78
Nonviral vectors for gene therapy.....	79
<i>Anionic lipid-DNA complexes</i> .....	80
<i>Cationic lipid-DNA complexes</i> .....	80
<i>Effects of shape of DNA molecules on delivery with nonviral vectors</i> .....	81
<i>Electrostatic modifications of surface to improve gene delivery</i> .....	81
<i>Liposomes for gene therapy</i> .....	81
<i>Liposome-nucleic acid complexes</i> .....	83
<i>Liposome-HVJ complex</i> .....	83
<i>Transposons DNA vectors</i> .....	84
<i>Polycation-DNA complexes (polyplexes)</i> .....	84
<i>Plasmid DNA vs minicircle DNA</i> .....	85
<i>Polymer vectors for gene therapy</i> .....	86
<i>Synthetic biology and DNA vectors</i> .....	87
<i>Synthetic peptide complexes</i> .....	87
<i>Future of nonviral vs viral vectors</i> .....	88
Nanobiotechnology for gene therapy.....	88
<i>Antisense nanoparticles</i> .....	88
<i>Dendrimers</i> .....	89
<i>Cochleates</i> .....	89
<i>Calcium phosphate nanoparticles as nonviral vectors</i> .....	89
<i>DNA nanoparticles as nonviral vectors</i> .....	89
<i>Gelatin nanoparticles for gene delivery</i> .....	90
<i>Lipid nanoparticles for nucleic acid delivery</i> .....	90
<i>Lipid nanoparticles for delivery of genome-editing proteins</i> .....	90
<i>Nanoparticles as nonviral vectors for gene therapy</i> .....	91
<i>Nanoparticles with virus-like function as gene therapy vectors</i> .....	91
<i>Nanobiologics for nucleic acid delivery</i> .....	92
<i>Nonionic polymeric micelles for oral gene delivery</i> .....	92
<i>Silica nanoparticles as a nonviral vector for gene delivery</i> .....	92
<i>Virus-like particles as nonviral vector</i> .....	92
Receptor-mediated endocytosis.....	93
Artificial viral vectors.....	94
Directed evolution of AAV to create efficient gene delivery vectors.....	94
Bacterial ghosts as DNA delivery systems.....	95
Bacteria plus nanoparticles for gene delivery into cells.....	95
Chromosome-based vectors for gene therapy.....	96
<i>Mammalian artificial chromosomes (MACs)</i> .....	96
<i>Human artificial chromosomes (HACs)</i> .....	97
<i>ΦC31 integrase system</i> .....	97
Companies using nonviral vectors.....	97
Concluding remarks about vectors.....	98

<b>Cell-mediated gene therapy</b> .....	<b>99</b>
Fibroblasts .....	100
Skeletal muscle cells .....	101
Vascular smooth muscle cells .....	101
Keratinocytes .....	101
Hepatocytes .....	102
Lymphocytes .....	102
<i>Regulating protein delivery by genetically encoded lymphocytes</i> .....	102
Implantation of microencapsulated genetically modified cells .....	102
Stem cell gene therapy .....	103
<i>Therapeutic applications for hematopoietic stem cell gene transfer</i> .....	104
<i>Improving delivery of genes to stem cells</i> .....	104
<i>Lentiviral vectors for gene transfer to marrow stem cells</i> .....	104
<i>Use of mesenchymal stem cells for gene therapy</i> .....	104
<i>Microporation for transfection of MSCs</i> .....	104
<i>In utero gene therapy using stem cells</i> .....	105
<i>Gene delivery to stem cells by artificial chromosome expression</i> .....	105
<i>Linker based sperm-mediated gene transfer technology</i> .....	105
<i>Combination of gene therapy with therapeutic cloning</i> .....	106
<i>Expansion of transduced HSCs in vivo</i> .....	106
<i>The future of hematopoietic stem cell gene therapy</i> .....	106
Role of genetically modified bacteria in gene therapy .....	106
<b>Routes of administration for gene therapy</b> .....	<b>107</b>
Direct injection of naked DNA .....	108
Intramuscular injection .....	108
Intravenous DNA injection .....	108
Intraarterial delivery .....	109
Companies with gene delivery devices/technologies .....	109
<b>Targeted gene therapy</b> .....	<b>110</b>
Targeted integration .....	110
Bacteriophage integrase system for site-specific gene delivery .....	111
Controlled-release delivery of DNA .....	111
<b>Controlled gene therapy</b> .....	<b>112</b>
Controlled delivery of genetic material .....	112
Controlled induction of gene expression .....	112
Drug-inducible systems for control of gene expression .....	113
Timed activation of gene therapy by a circuit based on signaling network .....	113
Small molecules for post-transcriptional regulation of gene expression .....	113
Light Activated Gene Therapy .....	114
Spatial control of gene expression via local hyperthermia .....	114
Companies with regulated /targeted gene therapy .....	114
<b>Gene marking</b> .....	<b>115</b>
<b>Germline gene therapy</b> .....	<b>115</b>
Potential applications of human germline genome modification .....	116
Pros and cons of human germline genome modification .....	116
<b>Role of gene transfer in antibody therapy</b> .....	<b>118</b>
<b>Genetically engineered vaccines</b> .....	<b>118</b>
DNA vaccines .....	118
<i>DNA inoculation technology</i> .....	119
<i>Methods for enhancing the potency of DNA vaccines</i> .....	119
<i>Advantages of DNA vaccines</i> .....	119
Vaccine vectors .....	120
Challenges and limitations of genetically engineered vaccines .....	121
RNA vaccines .....	121
<i>Nonviral delivery of self-amplifying RNA vaccine</i> .....	121
Vaccines based on reverse genetics .....	122
<b>Technologies for gene suppression</b> .....	<b>122</b>
Antisense oligonucleotides .....	122
Transcription factor decoys .....	123
Aptamers .....	123
Ribozymes .....	124
Peptide nucleic acid .....	124
<i>Intracellular delivery of PNAs</i> .....	124
Locked nucleic acid .....	125
<i>Zorro-LNA</i> .....	125
Gene silencing .....	125
Post-transcriptional gene silencing .....	125
Definitions and terminology of RNAi .....	126
RNAi mechanisms .....	126
Inhibition of gene expression by antigenic RNA .....	127
RNAi gene therapy .....	127

microRNA gene therapy .....	127
Viral vectors for RNAi and miRNA gene therapy .....	128
<b>Application of molecular diagnostic methods in gene therapy .....</b>	<b>129</b>
Use of PCR to study biodistribution of gene therapy vector .....	129
PCR for verification of the transcription of DNA .....	130
In situ PCR for direct quantification of gene transfer into cells .....	130
Detection of retroviruses by reverse transcriptase (RT)-PCR .....	130
Confirmation of viral vector integration .....	130
Monitoring of gene expression .....	130
<i>Monitoring of gene expression by green fluorescent protein</i> .....	131
<i>Monitoring in vivo gene expression by molecular imaging</i> .....	131
<i>Advantages of gene therapy compared with protein therapy</i> .....	131
<b>Formulation, transport and storage of materials for gene therapy .....</b>	<b>132</b>
<b>3. Clinical Applications of Gene Therapy .....</b>	<b>133</b>
<b>Introduction .....</b>	<b>133</b>
<b>Aging research .....</b>	<b>133</b>
<b>Bone and joint disorders .....</b>	<b>133</b>
Bone fractures .....	133
Gene therapy for intervertebral disc degeneration .....	134
Spinal fusion .....	135
Osteogenesis imperfecta .....	135
Rheumatoid arthritis .....	136
<i>Local or systemic treatment</i> .....	136
<i>In vivo or ex vivo gene therapy of RA</i> .....	136
<i>Clinical trials of gene therapy for rheumatoid arthritis</i> .....	137
Gene therapy for osteoarthritis .....	138
<i>Gene therapy strategies for osteoarthritis</i> .....	138
<i>Clinical trials of gene therapy for osteoarthritis</i> .....	140
Sports injuries .....	140
<i>Repair of articular cartilage defects</i> .....	140
Regeneration and replacement of bone by gene therapy .....	141
<b>Bacterial infections .....</b>	<b>142</b>
Antisense approach to bacterial infections .....	142
<b>Dentistry .....</b>	<b>142</b>
Tissue engineering in dental implant defects .....	142
<b>Endocrine and metabolic disorders .....</b>	<b>143</b>
Introduction .....	143
Gene therapy of obesity .....	143
<i>AAV vector-mediated delivery of GDNF for obesity</i> .....	143
<i>Oligopeptide for targeted nonviral gene delivery to adipocytes</i> .....	144
<i>Viral vector-mediated leptin gene therapy</i> .....	144
Diabetes mellitus .....	145
Methods of gene therapy of diabetes mellitus .....	145
<i>Viral vector-mediated gene transfer in diabetes</i> .....	146
<i>Endogenous reprogramming of a cells into <math>\beta</math> cells</i> .....	147
<i>Gene delivery with ultrasonic microbubble destruction technology</i> .....	147
<i>Genetically engineered cells for diabetes mellitus</i> .....	147
<i>Genetically altered liver cells</i> .....	148
<i>Genetically modified stem cells</i> .....	148
<i>Genetically engineered dendritic cells</i> .....	148
<i>Glucokinase and insulin co-expression</i> .....	148
<i>Leptin gene therapy</i> .....	149
<i>Concluding remarks about cell and gene therapy of diabetes</i> .....	149
Gene therapy of growth-hormone deficiency .....	150
<b>Gastrointestinal disorders .....</b>	<b>151</b>
Introduction .....	151
Methods of gene transfer to the gastrointestinal tract .....	151
<i>Direct delivery of genes</i> .....	151
<i>Naked plasmid DNA into the submucosa</i> .....	151
<i>Viral vectors</i> .....	151
<i>Receptor-mediated endocytosis</i> .....	152
Indications for gastrointestinal gene therapy .....	152
<i>Gene therapy for inflammatory disorders of the bowel</i> .....	153
Gene transfer to the salivary glands .....	153
<i>Potential clinical applications of salivary gene therapy</i> .....	154
<b>Hematology .....</b>	<b>154</b>
Hemophilias .....	154
<i>Gene therapy of hemophilia</i> .....	155
<i>Hemophilia A</i> .....	156
<i>Hemophilia B</i> .....	157

<i>Concluding remarks about gene therapy of hemophilias</i> .....	159
Hemoglobinopathies .....	159
<i>Gene therapy for <math>\beta</math>-thalassemia</i> .....	160
<i>Gene therapy for sickle cell disease</i> .....	161
<i>Gene therapy and RNAi for SCD based on stem cells</i> .....	161
<i>Gene editing in sickle cell disease</i> .....	162
<i>Gene editing using ZFN as treatment for both SCD and <math>\beta</math>-thalassemia</i> .....	162
<i>Gene editing using CRISPR-Cas9 for both SCD and <math>\beta</math>-thalassemia</i> .....	163
<i>Gene therapy of Fanconi's anemia</i> .....	163
Acquired hematopoietic disorders.....	164
<i>Chronic acquired anemias</i> .....	164
<i>Neutropenia</i> .....	164
<i>Thrombocytopenia</i> .....	165
Concluding remarks about gene therapy of hemoglobinopathies .....	166
Companies involved in gene therapy of hematological disorders .....	166
<b>In utero/fetal gene therapy</b> .....	<b>166</b>
Fetal gene transfer techniques.....	167
Animal models of fetal gene therapy .....	168
Potential applications of fetal gene therapy .....	168
<i>Fetal gene therapy for cystic fibrosis</i> .....	168
<i>Fetal intestinal gene therapy</i> .....	169
<i>Gene therapy for fetal growth restriction</i> .....	169
<b>Hearing disorders</b> .....	<b>169</b>
Potential of gene therapy .....	170
Vectors for gene therapy of hearing disorders.....	170
Auditory hair cell replacement and hearing improvement by gene therapy .....	171
<b>Kidney diseases</b> .....	<b>171</b>
End-stage renal disease.....	171
Methods of gene delivery to the kidney.....	172
<i>Gene transfer into kidney by adenoviral vectors</i> .....	172
<i>Non-viral gene transfer to the kidneys</i> .....	172
<i>Gene transfer into the glomerulus by HVJ-liposome</i> .....	173
<i>Bone marrow stem cells for renal disease</i> .....	173
<i>Mesangial cell therapy</i> .....	173
<i>Liposome-mediated gene transfer into the tubules</i> .....	174
<i>Gene transfer to tubules with cationic polymer polyethylenimine</i> .....	174
Gene therapy in animal experimental models of renal disease .....	174
Genetic manipulations of the embryonic kidney .....	175
Antisense intervention in glomerulonephritis .....	175
Gene therapy for renal fibrosis .....	175
Use of genetically engineered cells for uremia due to renal failure.....	176
Concluding remarks .....	176
<b>Liver disorders</b> .....	<b>176</b>
Techniques of gene delivery to liver .....	177
<i>Direct injection of DNA into liver</i> .....	177
<i>Local gene delivery by isolated organ perfusion</i> .....	178
<i>Liposome-mediated direct gene transfer</i> .....	178
<i>Retroviral vector for gene transfer to liver</i> .....	178
<i>Adenoviral vectors for gene transfer to liver</i> .....	178
<i>Receptor-mediated approach</i> .....	179
Cell therapy for liver disorders.....	179
<i>Transplantation of genetically modified hepatocytes</i> .....	179
<i>Genetically modified hematopoietic stem cells</i> .....	179
<i>Gene therapy by ex vivo transduced liver progenitor cells</i> .....	180
Gene therapy of genetic diseases affecting the liver .....	180
<i>Crigler-Najjar syndrome</i> .....	180
<i>Hereditary tyrosinemia type I (HT1)</i> .....	180
<i>Hereditary tyrosinemia type 3</i> .....	181
Gene therapy of acquired diseases affecting the liver .....	181
<i>Cirrhosis of liver</i> .....	181
<b>Ophthalmic disorders</b> .....	<b>182</b>
Introduction to gene therapy of ophthalmic disorders .....	182
Methods of gene therapy for ophthalmic disorders .....	183
<i>Delivery of gene therapy by intravitreal injection</i> .....	184
<i>DNA nanoparticles for nonviral gene transfer to the eye</i> .....	184
<i>Optogenetic gene therapy for blindness due to retinal degeneration</i> .....	185
Age-related macular degeneration .....	185
Inherited disorders of optic nerve affecting vision .....	186
<i>Leber hereditary optic neuropathy</i> .....	187
<i>Gene therapy for LHON</i> .....	187
Inherited retinal degenerations.....	188

<i>Choroideremia</i> .....	189
<i>Leber congenital amaurosis</i> .....	189
<i>Retinitis pigmentosa</i> .....	191
<i>Stargardt disease</i> .....	192
Other inherited disorders affecting vision .....	193
<i>Color blindness</i> .....	193
<i>Usher syndrome</i> .....	193
<i>X-linked retinoschisis</i> .....	195
Diabetic retinopathy .....	195
Future of gene therapy of inherited retinal degenerations .....	195
<i>Combining cell and gene therapies for retinal disorders</i> .....	196
Prevention of complications associated with eye surgery .....	196
<i>Prevention of proliferative retinopathy by gene therapy</i> .....	196
<i>Posterior capsule opacification after cataract surgery</i> .....	196
Autoimmune uveitis .....	197
Retinal ischemic injury .....	197
Corneal disorders .....	197
Glaucoma .....	198
Corneal scarring .....	198
Companies developing gene therapy for eye disorders .....	198
<b>Organ transplantation</b> .....	<b>199</b>
Introduction .....	199
DNA vaccines for transplantation .....	199
Gene therapy for prolonging allograft survival .....	199
<i>Genetically modified Tregs expressing CAR for preventing GVHD</i> .....	200
Gene therapy in lung transplantation .....	200
Role of gene therapy in liver transplantation .....	201
Gene therapy in kidney transplantation .....	201
Veto cells and transplant tolerance .....	201
<b>Pulmonary disorders</b> .....	<b>202</b>
Techniques of gene delivery to the lungs .....	202
<i>Adenoviral vectors</i> .....	203
<i>Nonviral vectors</i> .....	203
<i>Aerosolization as an aid to gene transfer to lungs</i> .....	204
Cystic fibrosis .....	204
<i>Genetics and clinical features</i> .....	204
<i>Gene therapy for CF</i> .....	204
<i>CFTR gene transfer in CF</i> .....	205
<i>Concluding remarks about gene therapy of CF</i> .....	206
Miscellaneous pulmonary disorders .....	206
<i>Gene therapy for pulmonary arterial hypertension</i> .....	207
<i>Gene therapy for bleomycin-induced pulmonary fibrosis</i> .....	207
<i>Gene therapy of emphysema due to <math>\alpha</math>1-antitrypsin deficiency</i> .....	208
<i>Gene therapy for asthma</i> .....	208
<i>Gene therapy for adult respiratory distress syndrome</i> .....	209
<i>Gene therapy for lung injury</i> .....	209
<i>Gene therapy for bronchopulmonary dysplasia</i> .....	209
Concluding remarks about gene therapy of lungs .....	210
Companies involved in pulmonary gene therapy .....	210
<b>Skin and soft tissue disorders</b> .....	<b>211</b>
Gene transfer to the skin .....	211
<i>Electroporation for transdermal delivery of plasmid DNA</i> .....	211
<i>Electroporation for transdermal delivery of DNA vaccines</i> .....	212
<i>Liposomes for transdermal gene delivery</i> .....	212
<i>Ultrasound and topical gene therapy</i> .....	212
Gene therapy in skin disorders .....	212
<i>Gene therapy of hair loss</i> .....	213
<i>Gene therapy for epidermolysis bullosa</i> .....	213
<i>Gene therapy for xeroderma pigmentosa</i> .....	215
<i>Gene therapy for lamellar ichthyosis</i> .....	215
Gene transfer techniques for wound healing .....	215
<b>Urogenital disorders</b> .....	<b>216</b>
Gene therapy for urinary tract dysfunction .....	216
Gene therapy for erectile dysfunction .....	216
<i>NOS gene transfer for erectile dysfunction</i> .....	216
<i>Clinical trial of hMaxi-K Gene transfer in erectile dysfunction</i> .....	217
<i>Gene therapy for erectile dysfunction due to nerve injury</i> .....	217
<i>Concluding remarks on gene therapy for erectile dysfunction</i> .....	217
<b>Veterinary gene therapy</b> .....	<b>217</b>
Gene therapy for mucopolysaccharidosis VII in dogs .....	218
Gene therapy to increase disease resistance .....	218



Gene therapy for infections .....	218
Gene therapy for chronic anemia .....	219
Gene therapy for endocrine disorders .....	219
Gene therapy for arthritis.....	219
Cancer gene therapy .....	220
<i>Brain tumors in cats and dogs</i> .....	220
<i>Breast cancer in dogs</i> .....	220
<i>Canine hemangiosarcoma</i> .....	221
<i>Canine melanoma</i> .....	221
<i>Canine soft tissue sarcoma</i> .....	222
Melanoma in horses .....	222
<b>4. Gene Therapy of Genetic Disorders.....</b>	<b>223</b>
<b>Introduction .....</b>	<b>223</b>
<b>Primary immunodeficiency disorders.....</b>	<b>224</b>
Severe combined immune deficiency .....	225
Chronic granulomatous disease .....	228
Wiskott-Aldrich syndrome .....	228
Purine nucleoside phosphorylase deficiency .....	229
Major histocompatibility class II deficiency .....	229
Future prospects of gene therapy of inherited immunodeficiencies .....	230
<b>Metabolic disorders.....</b>	<b>230</b>
Alpha1-antitrypsin deficiency.....	231
<i>AAV mediated gene therapy for <math>\alpha</math>1-antitrypsin deficiency</i> .....	231
<i>iPSCs for targeted gene correction of <math>\alpha</math>1-antitrypsin deficiency</i> .....	232
Adrenoleukodystrophy .....	233
Canavan disease.....	234
Lesch-Nyhan syndrome .....	235
Lipoprotein lipase deficiency.....	235
<i>Alipogene tiparvovec</i> .....	235
Ornithine transcarbamylase deficiency.....	236
<i>Gene therapy for OTCD</i> .....	236
<i>AAV-mediated gene editing for OTCD using CRISPR-Cas9</i> .....	237
Phenylketonuria.....	237
Porphyrias .....	238
Tetrahydrobiopterin deficiency.....	239
<b>Lysosomal storage disorders. ....</b>	<b>239</b>
Batten disease.....	240
Fabry's disease.....	241
Farber's disease.....	241
Gaucher disease .....	241
<i>Animals models of Gaucher's disease</i> .....	242
<i>Gene therapy of Gaucher's disease</i> .....	242
Hunter syndrome.....	243
Krabbe's disease.....	243
Metachromatic leukodystrophy .....	244
Mucopolysaccharidosis type 1 (Hurler syndrome) .....	245
Niemann-Pick type A disease.....	246
Pompe disease .....	246
Sanfilippo A syndrome.....	247
Sly syndrome .....	247
Tay-Sachs disease .....	248
Future prospects of gene therapy of lysosomal storage disorders .....	248
<b>Trinucleotide repeat disorders .....</b>	<b>249</b>
<b>Muscular dystrophies.....</b>	<b>249</b>
Duchenne muscular dystrophy (DMD).....	249
<i>Animal models for gene therapy of DMD</i> .....	250
<i>Antisense approaches to DMD</i> .....	250
<i>CRISPR/Cas9 gene editing for DMD</i> .....	250
<i>Exon-skipping for DMD</i> .....	251
<i>Galgt2 gene therapy</i> .....	252
<i>Liposome-mediated gene transfer</i> .....	252
<i>Microdystrophin gene therapy</i> .....	252
<i>Myoblast-based gene transfer in DMD</i> .....	253
<i>Plasmid-mediated gene therapy</i> .....	253
<i>Purinoreceptor P2RX7 ablation</i> .....	253
<i>Post-transcriptional modulation of gene expression in DMD</i> .....	254
<i>Repair/Editing of dystrophin gene</i> .....	254
<i>Routes of administration of gene therapy in DMD</i> .....	257
<i>Types of dystrophin constructs</i> .....	258
<i>Viral vectors for DMD</i> .....	258

<i>Conclusions and future of gene therapy of DMD</i> .....	259
Limb-girdle muscular dystrophy .....	260
Myotonic dystrophy .....	260
Spinal muscular atrophy .....	261
<i>Gene therapy for SMA</i> .....	261
<i>Antisense therapy of SMA</i> .....	262
<i>Nusinersen</i> .....	262
<i>Nusinersen vs scAAV9 gene therapy for SMA</i> .....	263
X-linked myotubular myopathy (XLMTM).....	263
<b>Hereditary neuropathies</b> .....	<b>263</b>
Charcot-Marie-Tooth disease .....	263
Hereditary axonal neuropathies of the peripheral nerves.....	264
<b>Gene therapy of mitochondrial disorders</b> .....	<b>264</b>
Techniques for mitochondrial replacement therapy.....	265
Status of mitochondrial replacement and transfer therapies .....	266
<b>Companies involved in gene therapy of genetic disorders</b> .....	<b>267</b>

<b>5. Gene Therapy of Cancer</b> .....	<b>269</b>
<b>Strategies for cancer gene therapy</b> .....	<b>269</b>
<b>Direct gene delivery to the tumor</b> .....	<b>270</b>
Injection into tumor .....	270
<i>Direct injection of adenoviral vectors</i> .....	270
<i>Direct injection of a plasmid DNA-liposome complex</i> .....	271
<i>A polymer approach to local gene therapy for cancer</i> .....	271
Electroporation for cancer gene therapy.....	271
Control of gene expression in tumor by local heat .....	272
Radiation-guided gene therapy of cancer .....	272
Radioprotective gene therapy of cancer .....	272
Nanoparticles to facilitate combination of hyperthermia and gene therapy.....	273
<b>Immunogene therapy of cancer</b> .....	<b>273</b>
<b>Cell-based cancer gene therapy</b> .....	<b>274</b>
Adoptive cell therapy .....	274
Cytokine gene therapy.....	275
Genetic modification of human hematopoietic stem cells.....	277
<b>Cancer vaccines</b> .....	<b>278</b>
Genetically modified cancer cell vaccines .....	278
<i>GVAX cancer vaccines</i> .....	278
<i>Genetically modified dendritic cells</i> .....	279
Nucleic acid-based cancer vaccines .....	279
<i>DNA cancer vaccines</i> .....	280
<i>RNA vaccines</i> .....	280
Viral vector-based cancer vaccines .....	280
<i>Intradermal delivery of cancer vaccines by Ad vectors</i> .....	281
Vaccines based on genetically engineered nonviral vectors.....	281
Future of cancer vaccines.....	281
Companies involved in nucleic acid-based cancer vaccines .....	282
<b>Monoclonal antibody gene transfer for cancer</b> .....	<b>283</b>
<b>Transfer and expression of intracellular adhesion-1 molecules</b> .....	<b>283</b>
<b>Other gene therapy techniques for immunotherapy of cancer</b> .....	<b>283</b>
Chemokines .....	283
CRISPR for immunogene therapy .....	284
Engineered viruses as anticancer immunotherapy vectors .....	285
Fas (Apo-1).....	285
Major Histocompatibility Complex (MHC) Class I .....	285
IGF (Insulin-Like Growth Factor).....	285
<b>Cancer immunotherapies targeting multiple mechanisms</b> .....	<b>285</b>
<b>Inhibition of immunosuppressive function in cancer</b> .....	<b>286</b>
<b>Delivery of toxic genes to tumor cells for eradication</b> .....	<b>286</b>
Gene-directed enzyme prodrug therapy .....	286
<b>Combination of gene therapy with radiotherapy</b> .....	<b>287</b>
<b>Correction of genetic defects in cancer cells</b> .....	<b>287</b>
<b>Targeted gene therapy for cancer</b> .....	<b>288</b>
Antiangiogenic therapy for cancer .....	288
Bacteria as novel anticancer gene vectors .....	289
Cancer-specific gene expression .....	289
Cancer-specific transcription.....	289
Delivery of retroviral particles hitchhiking on T cells .....	290
Electrogene and electrochemotherapy .....	290
Epidermal growth factor-mediated DNA delivery .....	290
Gene expression in hypoxic tumor cells .....	291
Genetically modified T cells for targeting tumors.....	291

<i>Chimeric antigen receptor T cells</i> .....	292
<i>CAR-T cells targeting both CD19 and CD22</i> .....	294
<i>Remote control of CAR-T cells</i> .....	294
Genetically engineered stem cells for targeting tumors .....	295
Hematopoietic stem cells for targeted cancer gene therapy .....	295
Immunolipoplex for delivery of p53 gene .....	296
Nanomagnets for targeted cell-based cancer gene therapy.....	296
Nanoparticles for targeted site-specific delivery of anticancer genes .....	296
Targeted cancer therapy using a dendrimer-based synthetic vector.....	297
Tumor-targeted gene therapy by receptor-mediated endocytosis .....	297
<b>Virus-mediated oncolysis.....</b>	<b>297</b>
Cytokine-induced killer cells for delivery of an oncolytic virus .....	298
Monitoring of viral-mediated oncolysis by PET .....	298
Oncolytic adenoviruses .....	298
Oncolytic HSV.....	300
Oncolytic measles viruses .....	300
Oncolytic vaccinia virus.....	301
Oncolytic vesicular stomatitis virus.....	301
Targeted cancer treatments based on oncolytic viruses.....	301
Concluding remarks on oncolytic gene therapy .....	302
<i>Companies developing oncolytic viruses</i> .....	302
<b>Apoptotic approach to improve cancer gene therapy .....</b>	<b>303</b>
<b>Tumor suppressor gene therapy .....</b>	<b>304</b>
P53 gene therapy.....	304
BRIT1 gene therapy .....	304
<b>Nitric oxide-based cancer gene therapy .....</b>	<b>304</b>
Anticancer effect of nitric oxide synthase .....	304
Gene therapy for radiosensitization of cancer .....	305
<b>Gene therapy of cancer of selected organs .....</b>	<b>305</b>
Gene therapy for bladder cancer.....	305
Gene therapy for glioblastoma multiforme. ....	306
<i>Adenoviral vectors for treatment of brain tumors</i> .....	307
<i>Antiangiogenic gene therapy</i> .....	307
<i>Autophagy induced by conditionally replicating adenoviruses</i> .....	308
<i>Baculovirus vector for diphtheria toxin gene therapy</i> .....	308
<i>Cerepro® (sitimagene ceradenovec)</i> .....	308
<i>Gene therapy targeting hepatocyte growth factor</i> .....	309
<i>Genetically engineered MSCs for gene delivery to intracranial gliomas</i> .....	309
<i>Intravenous gene delivery with nanoparticles into brain tumors</i> .....	309
<i>Ligand-directed delivery of dsRNA molecules targeted to EGFR</i> .....	310
<i>Olig2 targeting to hinder growth of treatment-resistant glioblastomas</i> .....	310
<i>RNAi gene therapy of brain cancer</i> .....	310
<i>Targeting normal brain cells with an AAV vector encoding interferon-β</i> .....	311
<i>Viral oncolysis of glioblastoma multiforme</i> .....	311
Gene therapy for breast cancer.....	313
<i>Gene vaccine for breast cancer</i> .....	313
<i>Recombinant adenoviral ErbB-2/neu vaccine</i> .....	314
Gene Therapy for ovarian cancer .....	314
Gene therapy for malignant melanoma .....	315
<i>Immunogene therapy</i> .....	315
<i>Nonviral immunogene therapy for malignant melanoma</i> .....	316
<i>Oncogene targeted therapy</i> .....	317
<i>Targeted gene therapy for malignant melanoma</i> .....	317
Gene therapy of lung cancer.....	317
<i>Intravenous nanoparticle formulation for delivery of FUS1 gene</i> .....	317
<i>Aerosol gene delivery for lung cancer</i> .....	318
Gene therapy for cancer of prostate .....	318
<i>Experimental studies</i> .....	318
<i>Nanoparticle-based gene therapy for prostate cancer</i> .....	319
<i>Tumor suppressor gene therapy in prostate cancer</i> .....	319
<i>Vaccines for prostate cancer</i> .....	319
<i>Viral oncolysis for prostate cancer</i> .....	320
<i>Clinical trials of gene therapy for prostate cancer</i> .....	320
Gene therapy of head and neck cancer .....	320
<i>Adenoviral vector based P53 gene therapy</i> .....	320
<i>Gene therapy as adjunct to 5-FU for nasopharyngeal carcinoma</i> .....	321
Gene therapy of pancreatic tumors .....	321
<i>Pancreatic neuroendocrine tumors</i> .....	321
<i>Pancreatic ductal adenocarcinoma</i> .....	321
<i>Correction of altered genes</i> .....	322
<i>Targeted gene therapy</i> .....	322

<i>Targeting in pancreatic adenocarcinoma with cell surface antigens</i> .....	323
<i>Targeted Expression of BikDD gene</i> .....	323
<i>Viral oncolysis in pancreatic cancer</i> .....	323
<i>Concluding remarks on gene therapy of pancreatic cancer</i> .....	324
Gene therapy of renal cancer.....	324
<i>Viral oncolytic therapy for renal cancer</i> .....	324
Gene therapy of hematological malignancies.....	324
<i>Genetically engineered T lymphocytes</i> .....	324
<b>Cancer gene therapy companies</b> .....	<b>325</b>

## **6. Gene Therapy of Neurological Disorders ..... 329**

<b>Indications</b> .....	<b>329</b>
<b>Gene transfer techniques for the nervous system</b> .....	<b>330</b>
Methods of gene transfer to the nervous system.....	330
Ideal vector for gene therapy of neurological disorders.....	330
Promoters of gene transfer.....	330
Lentivirus-mediated gene transfer to the CNS.....	331
AAV vector mediated gene therapy for neurogenetic disorders.....	331
Gene transfer to the CNS using recombinant SV40-derived vectors.....	332
Routes of delivery of genes to the nervous system.....	332
<i>Direct injection into CNS</i> .....	332
<i>Introduction of the genes into cerebral circulation</i> .....	333
<i>Introduction of genes into cerebrospinal fluid</i> .....	333
<i>Intravenous administration of vectors</i> .....	334
Delivery of gene therapy to the peripheral nervous system.....	334
Cell-mediated gene therapy of neurological disorders.....	334
<i>Neuronal cells</i> .....	334
<i>Neural stem cells and progenitor cells</i> .....	334
<i>Astrocytes</i> .....	335
<i>Cerebral endothelial cells</i> .....	335
<i>Implantation of genetically modified encapsulated cells into the brain</i> .....	335
Gene transfer for neuromodulation.....	336
<b>Gene therapy of neurodegenerative disorders</b> .....	<b>336</b>
Gene therapy for Parkinson disease.....	336
Rationale.....	337
<i>Techniques of gene therapy for PD</i> .....	337
<i>Augmenting CNS glucocerebrosidase activity</i> .....	341
<i>Delivery of neurotrophic factors by gene therapy</i> .....	341
<i>Delivery of parkin gene</i> .....	342
<i>Introduction of functional genes into the brain of patients with PD</i> .....	342
<i>Nanoparticle-based gene therapy for PD</i> .....	342
<i>Mitochondrial gene therapy for PD</i> .....	342
<i>RNAi approach to PD</i> .....	343
<i>Prospects of gene therapy for PD</i> .....	343
<i>Concluding remarks about gene therapy of PD</i> .....	344
<i>Companies developing gene therapy for PD</i> .....	344
Gene therapy for Alzheimer disease.....	345
Rationale.....	345
<i>NGF gene therapy for AD</i> .....	345
<i>FGF2 gene transfer in AD</i> .....	346
<i>Neprilysin gene therapy</i> .....	347
<i>Targeting plasminogen activator inhibitor type-1 gene</i> .....	347
<i>Viral gene transfer of APP<sub>sw</sub> for rescuing synaptic failure in AD</i> .....	347
<i>Gene vaccination</i> .....	348
<i>Combination of gene therapy with other treatments for AD</i> .....	348
Gene therapy of Huntington disease.....	348
<i>Encapsulated genetically engineered cellular implants</i> .....	348
<i>Viral vector mediated administration of neurotrophic factors</i> .....	349
<i>RNAi gene therapy</i> .....	349
Gene therapy of amyotrophic lateral sclerosis.....	349
Rationale.....	349
<i>Technique of gene therapy of ALS</i> .....	349
<i>Other approaches to gene therapy of ALS</i> .....	351
<b>Gene therapy of cerebrovascular diseases</b> .....	<b>351</b>
Preclinical research in gene therapy for cerebrovascular disease.....	351
Animal models of stroke relevant to gene therapy.....	351
<i>Transgenic mice as models for stroke</i> .....	352
<i>Animal models for gene therapy of arteriovenous malformations</i> .....	352
Gene transfer to cerebral blood vessels.....	352
Gene therapy for vasospasm following subarachnoid hemorrhage.....	353
<i>NOS gene therapy for cerebral vasospasm</i> .....	354

Gene therapy for stroke .....	354
<i>Gene therapy for stroke using neurotrophic factors</i> .....	356
<i>Gene therapy of strokes with a genetic component</i> .....	356
<i>Gene therapy for intracranial aneurysms</i> .....	356
<i>RNAi-based gene silencing for neuroprotection in cerebral ischemia</i> .....	357
Concluding remarks about gene therapy for stroke.....	357
<b>Gene therapy of injuries to the nervous system.....</b>	<b>358</b>
Traumatic brain injury .....	358
Spinal cord injury.....	358
Peripheral nerve injuries .....	359
<b>Gene therapy of epilepsy .....</b>	<b>359</b>
Gene therapy for control of seizures .....	360
Gene therapy for neuroprotection in epilepsy .....	361
Gene therapy for genetic forms of epilepsy .....	361
<b>Gene therapy for multiple sclerosis .....</b>	<b>362</b>
<b>Gene therapy for impairment of special senses .....</b>	<b>362</b>
Gene therapy for hearing loss.....	362
Gene therapy for olfactory impairment .....	363
<b>Gene therapy for relief of pain .....</b>	<b>364</b>
Rationale of gene therapy for pain .....	364
Vectors for gene therapy of pain .....	364
Methods of gene delivery for pain .....	364
<i>Endogenous analgesic production for cranial neuralgias</i> .....	365
<i>Gene delivery by intrathecal route</i> .....	365
<i>Gene transfer for delivery of analgesics to the spinal nerve roots</i> .....	366
<i>Gene therapy of peripheral neuropathic pain</i> .....	367
<i>Gene transfer by injections into the brain substance</i> .....	368
Targets for gene therapy of pain .....	368
<i>Zinc finger DNA-binding protein therapeutic for chronic pain</i> .....	368
<i>Gene therapy for producing enkephalin to block pain signals</i> .....	368
<i>Targeting nuclear factor-<math>\kappa</math>B</i> .....	369
<i>Gene therapy targeted to neuroimmune component of chronic pain</i> .....	369
Potential applications of gene therapy for management of pain.....	370
Concluding remarks on gene therapy for pain.....	370
<b>Gene therapy for psychiatric disorders .....</b>	<b>371</b>
Gene therapy for depression .....	371
Gene therapy for enhancing cognition after stress.....	372
Gene therapy against fear disorders.....	372
<b>Companies involved in gene therapy of neurological disorders.....</b>	<b>372</b>

<b>7. Gene Therapy of Cardiovascular Disorders .....</b>	<b>375</b>
<b>Introduction .....</b>	<b>375</b>
<b>Techniques of gene transfer to the cardiovascular system .....</b>	<b>375</b>
Direct plasmid injection into the myocardium .....	376
Catheter-based systems for vector delivery .....	376
Ultrasound microbubbles for cardiovascular gene delivery .....	377
Vectors for cardiovascular gene therapy .....	377
<i>AAV vectors for therapeutic delivery to the heart</i> .....	377
<i>Adenoviral vectors for cardiovascular diseases</i> .....	378
<i>Molecular cardiac surgery with recirculating delivery of AAV vectors</i> .....	378
<i>Plasmid DNA-based delivery in cardiovascular disorders</i> .....	378
Gene therapy for counteracting hypoxia in myocardial ischemia.....	378
Therapeutic angiogenesis vs vascular growth factor therapy.....	379
Gene painting for delivery of targeted gene therapy to the heart .....	379
Gene delivery to vascular endothelium .....	380
Targeted plasmid DNA delivery to the cardiovascular system with nanoparticles .....	380
Vascular stents for gene delivery .....	381
<b>Gene therapy for genetic cardiovascular disorders .....</b>	<b>381</b>
Catecholaminergic polymorphic ventricular tachycardia.....	381
Genetic disorders predisposing to atherosclerosis.....	382
Familial hypercholesterolemia.....	383
Apolipoprotein E deficiency.....	384
Hypertension.....	385
Genetic factors for myocardial infarction .....	385
<b>Acquired cardiovascular diseases .....</b>	<b>386</b>
Coronary artery disease with angina pectoris.....	386
<i>Ad5FGF-4</i> .....	386
Gene therapy for improving long-term CABG patency rates.....	387
Ischemic heart disease with myocardial infarction .....	387
<i>Gene therapy and angiogenesis in ischemic heart disease</i> .....	388
<i>Induction of angiogenesis in myocardium by HEXIM1 re-expression</i> .....	388

Myocardial repair with IGF-1 therapy.....	389
Metalloproteinase-2 inhibitor gene therapy.....	389
miRNA gene therapy for ischemic heart disease.....	390
Congestive heart failure.....	390
Rationale of gene therapy in CHF.....	390
AAV-mediated gene transfer for CHF.....	391
AngioCell gene therapy for CHF.....	391
β-ARKct gene therapy.....	392
Elevating cardiac dATP by gene therapy to improve cardiac function.....	392
Elevating cardiac adenyl cylase type 6 to improve cardiac function.....	393
Intracoronary adenovirus-mediated gene therapy for CHF.....	394
nNOS gene transfer in CHF.....	394
Cardiomyopathies.....	394
Cardiac conduction disturbances.....	395
Gene transfer approaches for biological pacemakers.....	395
Genetically engineered biological pacemakers.....	396
Gene therapy and heart transplantation.....	396
Hyperlipidemia and hypercholesterolemia.....	397
Antisense approach to hypertriglyceridemia.....	397
Cholesterol reduction by genetic engineering of PCSK9 gene.....	397
Inactivating variants in ANGPTL4 for lowering circulating triglycerides.....	397
<b>Peripheral arterial disease.....</b>	<b>398</b>
Incidence and clinical features.....	398
Current management.....	398
Gene therapy for peripheral arterial disease.....	398
Angiogenesis by gene therapy.....	398
HIF-1α gene therapy for peripheral arterial disease.....	399
HGF gene therapy for peripheral arterial disease.....	399
Prevention of restenosis after angioplasty.....	400
Antisense approaches.....	400
Gene therapy to prevent restenosis after angioplasty.....	401
hTIMP-1 gene therapy to prevent intimal hyperplasia.....	402
miRNA-based gene therapy for restenosis.....	402
NOS gene therapy for restenosis.....	403
Techniques of gene therapy for restenosis.....	403
Maintaining vascular patency after surgery.....	404
<b>Companies involved in gene therapy of cardiovascular diseases.....</b>	<b>404</b>
Future of gene therapy of cardiovascular disorders.....	405

## **8. Gene therapy of viral infections..... 407**

<b>Introduction.....</b>	<b>407</b>
<b>Acquired Immunodeficiency Syndrome (AIDS).....</b>	<b>407</b>
Current management of AIDS.....	407
Gene therapy strategies in HIV/AIDS.....	408
HIV/AIDS vaccines.....	408
Insertion of protective genes into target cells.....	409
Cell/gene therapies for HIV/AIDS.....	410
Transplantation of genetically modified T cells.....	410
Transplantation of genetically modified hematopoietic cells.....	411
Anti-HIV ribozyme delivered in hematopoietic progenitor cells.....	412
Gene editing for HIV-1.....	412
Inhibition of HIV-1 replication by lentiviral vectors.....	412
VRX496-T.....	413
Intracellular immunization.....	413
Engineered cellular proteins such as soluble CD4s.....	414
Intracellular antibodies.....	414
Anti-rev single chain antibody fragment.....	414
Use of genes to chemosensitize HIV-1 infected cells.....	414
Autocrine interferon (INF)-β production by somatic cell gene therapy.....	415
Antisense approaches to AIDS.....	415
RNA decoys.....	415
Antisense oligodeoxynucleotides.....	415
RNA decoys.....	415
Ribozymes.....	416
RNAi applications in HIV/AIDS.....	416
siRNA-directed inhibition of HIV-1 infection.....	417
Role of the nef gene during HIV-1 infection and RNAi.....	417
Bispecific siRNA constructs.....	417
Targeting CXCR4 with siRNAs.....	418
Targeting CCR5 with siRNAs.....	418
Companies involved in developing gene therapy for HIV/AIDS.....	419

Conclusions regarding gene therapy of HIV/AIDS.....	419
<b>Genetic vaccines for other viral infections .....</b>	<b>420</b>
Cytomegalic virus infections .....	420
Viral hepatitis .....	421
<i>Vaccine for hepatitis B</i> .....	421
<i>Vaccine for hepatitis C</i> .....	421
<i>Gene therapy for hepatitis C</i> .....	421
Vaccine for herpes simplex virus .....	422
DNA vaccine against rabies .....	422
DNA vaccine for Ebola .....	423
Vaccines for avian influenza .....	423
<i>Future prospects of DNA vaccines for avian influenza</i> .....	424
<i>Human trial of a DNA vaccine for avian influenza</i> .....	424
Companies developing genetic vaccines for infections other than AIDS .....	425
<b>9. Research, Development and Future of Gene Therapy.....</b>	<b>427</b>
<b>Basic research in gene therapy .....</b>	<b>427</b>
<b>R &amp; D in gene therapy .....</b>	<b>427</b>
Animal models of human diseases for gene therapy research .....	428
<i>Lentiviral transgenesis</i> .....	428
<b>Financing research and development.....</b>	<b>428</b>
Role of the NIH in gene therapy research .....	428
National Gene Vector Laboratories .....	428
Funding of gene therapy research in Europe .....	429
<i>Gene therapy funding in Horizon 2020 of European Commission</i> .....	429
Financing by the industry .....	430
<b>Clinical trials in gene therapy .....</b>	<b>430</b>
Clinical trials worldwide .....	430
<i>Clinical trials in cancer gene therapy</i> .....	431
<i>Trials of gene therapy for neurological disorders</i> .....	431
<i>Clinical trials for genetic disorders</i> .....	431
<i>Clinical trials in cardiovascular gene therapy</i> .....	431
<i>Clinical trials for infectious diseases</i> .....	431
<i>Gene therapy for other disorders</i> .....	431
Clinical trials in the US .....	432
Vectors used in gene therapy clinical trials .....	432
<i>Vector analytics for clinical trials using rAAV vectors</i> .....	433
<b>Gene therapy in China.....</b>	<b>433</b>
<b>Future of gene therapy .....</b>	<b>434</b>
How to improve gene therapy.....	434
International Gene Therapy Consortium.....	435
Future opportunities and challenges for gene therapy .....	436
Promising areas of application of gene therapy .....	437
<i>Neurological disorders</i> .....	437
<i>Gene therapy of cardiovascular disorders</i> .....	438
<i>Cancer gene therapy</i> .....	439
Personalized gene therapy .....	440
<b>10. Regulatory, Safety, Ethical Patent Issues of Gene Therapy .....</b>	<b>441</b>
<b>Regulation of gene therapy in the United States.....</b>	<b>441</b>
US Federal guidelines for research involving recombinant DNA molecules .....	441
Regulation of gene therapy in US .....	441
Implantation of genetically manipulated cells.....	441
<i>Modification of oocytes for use in IVF</i> .....	442
Clinical trials in gene therapy .....	442
Cell and gene therapy INDs placed on hold by the FDA .....	442
Do-it-yourself gene therapy .....	443
<b>Regulation of gene therapy in Europe.....</b>	<b>443</b>
European Union .....	443
Regulation of gene therapy in Germany .....	444
<i>Preclinical research</i> .....	445
<i>Clinical Trials</i> .....	445
Marketing authorization .....	446
Regulation of gene therapy in the United Kingdom .....	446
Regulation of gene therapy in France.....	447
Regulation of gene therapy in Italy .....	447
Regulation of gene therapy in the Netherlands.....	448
Gene therapy regulation in Switzerland.....	449
<b>Regulation of gene therapy in Australia .....</b>	<b>449</b>
<b>Regulation of gene therapy in Japan.....</b>	<b>450</b>
<b>Regulation of gene therapy in China .....</b>	<b>451</b>

<b>Safety issues of gene transfer .....</b>	<b>451</b>
Adverse effects of retroviral vectors .....	451
<i>Insertional mutagenesis</i> .....	451
Adverse effects of HSV vectors .....	452
<i>Neurotoxicity of HSV vectors</i> .....	452
<i>Hepatotoxicity of HSV-tk/ganciclovir approach</i> .....	453
Adverse effects of adenoviral vectors.....	453
<i>Inflammatory effects of adenoviruses in lungs</i> .....	453
<i>Inflammatory effects involving the liver</i> .....	453
<i>Induction of immune response by adenoviral vectors</i> .....	454
<i>Impairment of adrenocortical steroidogenesis</i> .....	454
<i>Adverse effects of AAV vectors</i> .....	454
Toxicity associated with cationic lipid-mediated gene transfer.....	455
Toxicity of lipopolysaccharides .....	455
Potential side effects of RNAi gene therapy.....	455
Role of molecular diagnostics in safety of gene therapy .....	456
Quality control of vectors .....	456
<i>Testing for retroviruses</i> .....	456
<i>Adenoviral vectors</i> .....	457
<i>Replication competent viruses</i> .....	457
Genetic characteristics of viral vectors .....	457
Concluding remarks about safety of viral vectors .....	457
<b>Ethical aspects of gene therapy .....</b>	<b>458</b>
The lay consumer's view of somatic gene therapy ethics.....	458
Ethical aspects of clinical trials.....	459
Regulatory and ethical issues for in utero gene therapy .....	459
Ethical aspects of germline gene therapy .....	459
Ethical aspects of mitochondrial replacement therapy .....	460
Ethical aspects of gene editing.....	461
<i>Ethical aspects of clinical trials of germline editing</i> .....	461
<i>Gene editing in the UK</i> .....	461
<i>Gene editing in the US</i> .....	462
<i>UNESCO's view on gene editing in humans</i> .....	463
Germline gene therapy for genetic enhancement .....	464
Athletic enhancement by genetic engineering .....	464
<i>Gene doping in sports</i> .....	464
<i>Gene transfer methods used for enhancing physical performance</i> .....	464
<i>Adverse effect of genetic engineering</i> .....	466
<i>Problems in detecting genetic manipulations in athletes</i> .....	467
<i>Ethical dilemma</i> .....	467
<b>Gene therapy patents .....</b>	<b>468</b>
CRISP/Cas9 patents .....	468
<b>11. Markets for Gene Therapy .....</b>	<b>471</b>
<b>Introduction .....</b>	<b>471</b>
<b>Gene therapy markets in various regions of the world.....</b>	<b>471</b>
<b>Gene therapy markets according to therapeutic areas.....</b>	<b>472</b>
Cancer gene therapy market .....	472
Markets for gene therapy of genetic disorders .....	473
<b>Markets for DNA vaccines .....</b>	<b>473</b>
DNA vaccines markets according to technologies .....	473
DNA vaccines markets according to therapeutic indications .....	474
DNA vaccines markets according to geographical areas .....	474
<b>Competing treatments .....</b>	<b>475</b>
Antisense.....	475
RNAi.....	475
Cell therapy .....	476
<b>Strategies for developing gene therapy markets .....</b>	<b>476</b>
<i>Collaboration with pharmaceutical companies</i> .....	476
<i>Collaboration with companies developing cell-based therapies</i> .....	476
<i>Collaboration with academic gene therapy centers</i> .....	476
<i>Developing safer and cost-effective gene medicines</i> .....	476
<i>Intellectual property and commercialization of gene therapy</i> .....	477
<i>Overcoming obstructions to the development of gene therapy</i> .....	477
<b>Unmet needs in gene therapy .....</b>	<b>478</b>
<b>Promises and challenges for the development of gene therapy .....</b>	<b>479</b>
Development of gene therapy market in China .....	479
Challenges of developing gene therapy in the USA .....	479
Challenges of developing gene therapy in the European Union.....	479
<b>12. References .....</b>	<b>481</b>



## Tables

Table 1-1: Landmarks in development of gene therapy.....	23
Table 2-1: Classification of methods of gene therapy.....	35
Table 2-2: A comparison of various physical methods of gene transfer .....	37
Table 2-3: Experimental applications of gene transfer by electroporation .....	39
Table 2-4: CRISPR vs other gene editing tools.....	49
Table 2-5: Companies developing CRISPR technology .....	59
Table 2-6: An overview of characteristics of commonly used viral vectors .....	65
Table 2-7: Companies using viral vectors.....	78
Table 2-8: Companies using nonviral vectors .....	98
Table 2-9: Target organs for nonviral gene therapy methods. ....	99
Table 2-10: Potential routes for administration of DNA .....	107
Table 2-11: Companies with gene delivery devices/ technologies.....	109
Table 2-12: Strategies for targeted gene therapy .....	110
Table 2-13: Animal experimental studies of in vivo gene delivery with polymer systems.....	111
Table 2-14: Approaches to controlling gene expression in gene therapy .....	112
Table 2-15: Companies with regulated/targeted gene therapy and special techniques .....	114
Table 2-16: Potential applications of human germline genome modification .....	116
Table 2-17: Applications of molecular diagnostics in gene therapy .....	129
Table 2-18: Advantages of gene therapy compared with protein therapy .....	132
Table 3-1: Experimental approaches to gene therapy of rheumatoid arthritis .....	137
Table 3-2: Gene therapy strategies for osteoarthritis.....	139
Table 3-3: Cell and gene therapy approaches for type 1 diabetes mellitus.....	145
Table 3-4: Indications for gastrointestinal gene therapy .....	152
Table 3-5: Hematological disorders that can be potentially treated by gene therapy.....	154
Table 3-6: Clinical trials of gene therapy for hemophilia A and B.....	155
Table 3-7: Companies involved in gene therapy of hematological disorders.....	166
Table 3-8: Techniques of gene transfer to the kidneys.....	172
Table 3-9: Gene therapy in animal experimental models of renal disease.....	174
Table 3-10: Applications of gene therapy in ophthalmological disorders .....	182
Table 3-11: Companies developing gene therapy for eye disorders .....	199
Table 3-12: Strategies for gene delivery to the lungs .....	202
Table 3-13: Companies developing gene therapy for pulmonary disorders .....	211
Table 4-1: Genetic disorders that are being investigated for gene therapy .....	223
Table 4-2: X-linked immunodeficiency disorders .....	225
Table 4-3: Examples of inherited metabolic disorders amenable to gene therapy .....	230
Table 4-4: Gene therapy approaches to Duchenne muscular dystrophy .....	249
Table 4-5: Companies involved in gene therapy of genetic/metabolic disorders .....	267
Table 5-1: Strategies for cancer gene therapy .....	269
Table 5-2: Cell-based gene therapy for cancer .....	274
Table 5-3: Companies with nucleic acids/genetically modified cell cancer vaccines .....	282
Table 5-4: Enzyme/prodrug combinations employed in suicide gene therapy .....	286
Table 5-5: Mutation compensation strategies used clinically .....	287
Table 5-6: Companies developing oncolytic viruses .....	302
Table 5-7: Strategies for gene therapy of malignant brain tumors.....	306
Table 5-8: Clinical trials of oncolytic virotherapy against glioblastoma multiforme.....	312
Table 5-9: Clinical trials of gene therapy in ovarian cancer.....	314
Table 5-10: Gene therapy for malignant melanoma.....	315
Table 5-11: Clinical trials of gene therapy for prostate cancer .....	320
Table 5-12: Companies involved in cancer gene therapy.....	325
Table 6-1: Example of potential indications for gene therapy of neurologic disorder .....	329
Table 6-2: Methods of gene transfer as applied to neurologic disorders .....	330
Table 6-3: Gene therapy techniques applicable to Parkinson disease .....	336
Table 6-4: Companies developing gene therapy for Parkinson's disease.....	344
Table 6-5: Gene transfer in animal models of carotid artery restenosis.....	353
Table 6-6: Gene therapy strategies for vasospasm.....	353
Table 6-7: Neuroprotective gene therapy in animal stroke models .....	355
Table 6-8: Experimental gene therapy approaches for relief of pain .....	365
Table 6-9: Companies involved in gene therapy of neurological disorders .....	373
Table 7-1: Cardiovascular disorders that are potential indications for gene therapy.....	375
Table 7-2: Catheter-based systems for vector delivery to the cardiovascular system.....	376
Table 7-3: Companies involved in gene therapy of cardiovascular diseases .....	404
Table 8-1: Strategies for gene therapy of AIDS .....	408
Table 8-2: Companies involved in developing gene therapy for HIV/AIDS .....	419
Table 8-3: Companies developing genetic vaccines for infections other than AIDS .....	425
Table 9-1: Geographical distribution of gene therapy clinical trials .....	430
Table 9-2: Opportunities and challenges for gene therapy and resources needed .....	437
Table 9-3: Potential applications of gene therapy in disorders of the nervous system .....	438
Table 10-1: Genes that may be used for performance enhancement .....	465
Table 11-1: Gene therapy market according to regions/countries – 2017 to 2027 .....	471

Table 11-2: Gene therapy markets according to therapeutic areas – 2017 to 2027.....	472
Table 11-3: Cancer gene therapy market according to type of cancer - 2017 to 2027.....	472
Table 11-4: Gene therapy market for selected genetic disorders - 2017 to 2027.....	473
Table 11-5: DNA vaccines markets according to technologies - 2017 to 2027.....	474
Table 11-6: DNA vaccines markets according to therapeutic indications - 2017 to 2027.....	474
Table 11-7: DNA vaccines markets according to geographical areas - 2017 to 2027.....	474

## Figures

Figure 1-1: Relation of gene therapy to other biotechnologies .....	25
Figure 1-2: Relationship of DNA, RNA and protein in the cell .....	29
Figure 2-1: Ex vivo and in vivo techniques of gene therapy.....	36
Figure 2-2: Structure of the Helios gene gun.....	42
Figure 2-3: A scheme of CRISPR/Cas9 gene editing .....	48
Figure 2-4: Use of CRISPR-Cas9 for hereditary hearing loss.....	57
Figure 2-5: Gene editing vs suppression of gene expression.....	61
Figure 2-6: Categories of rAAV-based gene therapy strategies .....	68
Figure 2-7: Bacteria plus nanoparticles for drug delivery into cells .....	95
Figure 2-8: Schematic of suppression of gene expression by RNAi .....	126
Figure 3-1: Retina and routes of administration of gene therapy for retinal disorders .....	188
Figure 4-1: Targeted gene correction of $\alpha$ 1-antitrypsin deficiency by iPSCs .....	233
Figure 4-2: Application of CRISPR-Cas9 in a mouse model of DMD.....	256
Figure 4-3: Techniques for mitochondrial nuclear transfer.....	265
Figure 5-1: Chimeric antigen receptor (CAR)-T cells attacking tumor cells.....	292
Figure 5-2: Gene therapy approaches for pancreatic cancer .....	322
Figure 6-1: Effect of tyrosine hydroxylase gene delivery on dopamine levels .....	338
Figure 6-2: Role of cell and gene therapy in stroke according to pathology and stage.....	358
Figure 9-1: Product development cycle in gene therapy.....	427
Figure 9-2: Proportions of therapeutic areas in clinical trials of gene therapy in the US.....	432
Figure 9-3: Proportions of various vectors used in gene therapy trials .....	432
Figure 10-1: Evaluation system of gene therapy clinical studies in Japan .....	450
Figure 11-1: Unmet needs in gene therapy .....	478